Scorpio fuscus venom as a promising anticancer agent against colorectal cancer.
1/5 보강
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, underscoring the urgent need for novel and effective therapeutic agents.
APA
Karakurt S, Gokcek-Sarac C, et al. (2026). Scorpio fuscus venom as a promising anticancer agent against colorectal cancer.. Investigational new drugs, 44(1), 23-38. https://doi.org/10.1007/s10637-026-01598-z
MLA
Karakurt S, et al.. "Scorpio fuscus venom as a promising anticancer agent against colorectal cancer.." Investigational new drugs, vol. 44, no. 1, 2026, pp. 23-38.
PMID
41627596 ↗
Abstract 한글 요약
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, underscoring the urgent need for novel and effective therapeutic agents. Conventional treatments, including chemotherapy, radiotherapy, and surgery, are often associated with significant adverse effects, prompting the exploration of alternative therapeutic strategies. This study aimed to evaluate the anticancer effects of Scorpio fuscus venom (SFV) on human colorectal cancer models using integrated in vitro and in vivo approaches. SFV constituents were characterized using gel electrophoresis, followed by high-performance liquid chromatography and UV-visible spectrometry. Identified peptides were subjected to structural modeling and in silico docking analyses against selected proteins associated with colorectal cancer and apoptosis-related pathways. The cytotoxic effects of SFV were assessed in human CRC cell lines (DLD-1, HT-29, and CaCo-2) and a healthy colon epithelial cell line (CCD-18Co) using Alamar Blue assays after 48-h treatment, and half-maximal inhibitory concentration (IC₅₀) values were determined. SFV treatment resulted in a dose-dependent reduction in cancer cell viability, accompanied by decreased migratory capacity and colony formation ability. Apoptotic responses were further evaluated by flow cytometry and gene expression analyses, indicating modulation of apoptosis-associated genes. For in vivo validation, subcutaneous and orthotopic xenograft colon cancer models were established in mice. SFV administration led to reduced tumor growth compared with control groups. Immunohistochemical analyses revealed altered expression patterns of selected tumor-related markers in SFV-treated tumors. Gene expression profiling demonstrated ≥ twofold changes in 51 genes, including downregulation of BAK1 and TRAF3, and upregulation of BIRC2, BIRC3, BIRC6, CASP8, TNFRSF8, TNFRSF11, and BOK. Collectively, these findings indicate that SFV exerts significant antitumor effects in colorectal cancer models and support its potential as a promising anticancer agent, warranting further mechanistic and translational investigation.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Animals
- Humans
- Colorectal Neoplasms
- Antineoplastic Agents
- Apoptosis
- Cell Line
- Tumor
- Xenograft Model Antitumor Assays
- Mice
- Cell Survival
- Nude
- Inbred BALB C
- Molecular Docking Simulation
- HT29 Cells
- Cell Movement
- Female
- Cell Proliferation
- Scorpio fuscus
- Colorectal carcinoma
- In vivo
- Molecular mechanism
- Signaling pathways
- Venom
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.